Raynaud Disease: all 81 studies

Page 1 of 1. Open to participants first (8), then studies with results posted, then the rest; newest registration first within each.

• A Study of LIQ861 (Inhaled Treprostinil) in Adults With Systemic Sclerosis Who Have Symptomatic Raynaud's Phenomenon AttacksNot yet recruitingNCT07748000Phase 2
• Emerging Indications for Hyperbaric Oxygen TreatmentNot yet recruitingNCT07240649Phase 4
• Open Label Treprostinil Raynaud's StudyRecruitingNCT07112183Phase 4
• Multi-modal Quantitative Imaging of the SkinRecruitingNCT06989216
• The Apollo Device in Systemic Sclerosis for the Management of fatiguE, Raynaud Phenomenon and qualiTy of LifeRecruitingNCT06675344Not applicable
• Evaluation of Botulinum TOXin Type A in the Treatment of Buerger's DiseaseNot yet recruitingNCT05698979Phase 3
• Follow-up of SPTS in Patients With Raynaud's PhenomenonRecruitingNCT04015193
• Application for Monitoring and Evaluation of Raynaud's PhenomenonRecruitingNCT03984422
• Botulinum Toxin in Raynaud's PhenomenonCompletedNCT05125029Phase 4Results posted
• A Study to Assess the Effect of Oral Temanogrel on Digital Blood Flow in Adult Participants With Raynaud's Phenomenon Secondary to Systemic SclerosisTerminatedNCT04915950Phase 2Results posted
• Apollo Device for Fatigue in Systemic SclerosisCompletedNCT04854850Not applicableResults posted
• Cold Challenge With C21 in RPCompletedNCT04388176Phase 2Results posted
• Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)CompletedNCT04040322Phase 3Results posted
• Potential Benefit for Non Invasive Vagus Nerve Stimulation Using GammaCore in the Treatment of Raynaud's Phenomena.TerminatedNCT03869008Not applicableResults posted
• Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)CompletedNCT03867097Phase 2Results posted
• The Effect of Abobotulinum Toxin A on the Symptoms of Raynaud's PhenomenonTerminatedNCT03639766Phase 4Results posted
• Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's PhenomenonCompletedNCT03129178Not applicableResults posted
• Exparel as a Nerve Block for Severe Hand PainTerminatedNCT02374320Phase 2/3Results posted
• Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's SyndromeCompletedNCT02165111Phase 3Results posted
• Effect of Sildenafil on the Microcirculatory Blood Flow and Endothelial Progenitor Cells in Systemic SclerosisCompletedNCT01347008Phase 3Results posted
• A Two-Part Study of BOTOX® Therapy for Ischemic DigitsCompletedNCT01309802Phase 2Results posted
• Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud PhenomenonCompletedNCT01280266Phase 2/3Results posted
• Botulinum Toxin in the Treatment of Raynaud'sCompletedNCT01233999Not applicableResults posted
• PF-00489791 For The Treatment Of Raynaud'sCompletedNCT01090492Phase 2Results posted
• Tadalafil for the Treatment of Raynaud'sCompletedNCT00822354Not applicableResults posted
• A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's PhenomenonCompletedNCT00498615Phase 3Results posted
• Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s PhenomenonCompletedNCT00251238Phase 2Results posted
• Treatment of Frostbite Sequelae With Botulinum Toxin AWithdrawnNCT06460194Phase 2
• Early Diagnosis of SSc in the General Rheumatology Clinic - PilotCompletedNCT06291142
• Rheopheresis for Raynaud's and Digital Ulcers in Systemic SclerosisStatus unknownNCT05204784Not applicable
• Phototherapy For Treatment Of Raynaud's PhenomenonWithdrawnNCT04898036Not applicable
• Functional Exercise Tests in Patients With Systemic SclerosisStatus unknownNCT04650659
• Dermoscopy in Primary Raynaud's PhenomenonCompletedNCT04644523
• Localized Effects of PBM and Exogenous NO on CREST Patients Calcinosis Cutis & Raynaud PhenomenonStatus unknownNCT03972566
• Cocoa Flavanol Supplementation in Raynaud's PhenomenonCompletedNCT03815162Not applicable
• Nutritional Strategies to Increase Nitric Oxide Signaling in Raynaud's PhenomenonStatus unknownNCT03749577Not applicable
• Efficacy of Botulinum Toxin A in Adult Subjects With Raynaud Phenomenon Secondary to Systemic SclerosisCompletedNCT03717961Phase 3
• Effectiveness of Electric Stimulation Therapy in Raynaud's PhenomenonCompletedNCT03699436Not applicable
• Tadalafil-Delivra and Raynaud's PhenomenonWithdrawnNCT03393325
• Identification of TRP Channels as New Potential Therapeutic Targets in Primary and Secondary Raynaud's Phenomenon.CompletedNCT03211325Not applicable
• Investigation of the Rewarming og the Fingers After Cooling and the Autonomic Nervous System in Raynaud's PhenomenonCompletedNCT03094910Not applicable
• The Effects of Exercise in Patients With Systemic SclerosisCompletedNCT03058887Not applicable
• Topical 10 % Nifedipine Versus 5% Sildenafil in Secondary RaynaudCompletedNCT03027674Early Phase 1
• Diosmiplex (Vasculera®) in Primary and Secondary Raynaud's PhenomenonCompletedNCT02683408Not applicable
• Treatment of Digital Ulcers in Korean Patients With Systemic Sclerosis: a Prospective Cohort StudyTerminatedNCT02642146
• Nova Cold Hands Raynaud's Disorder, a Disease Which Results in Decreased Blood Flow to the Hands and Feet.CompletedNCT02615964
• Assess Efficacy of of Oral Treprostinil in Patients With Symptomatic Primary or Secondary Raynaud's PhenomenonCompletedNCT02583789Early Phase 1
• CSL Behring Sclero XIIIStatus unknownNCT02551042Phase 2
• A Trial of Ischemic Preconditioning in Raynaud's Phenomenon (RP)CompletedNCT02506062Not applicable
• Scleroderma Treatment With Celution Processed Adipose Derived Regenerative Cells (STAR)CompletedNCT02396238Not applicable
• Safety and Efficacy Study of Gene Therapy Drug (Neovasculgen) to Treat Secondary Raynaud's PhenomenonStatus unknownNCT02356809Phase 1/2
• Metabolomic Analysis of Systemic SclerosisTerminatedNCT02298777
• Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT02260557Phase 2
• Study of Acute Peripheral Vascular Effects, Safety and Tolerability in Subjects With Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT02228850Phase 2
• Prospective Multicenter Study on the Identification of Genetic Abnormalities Predisposing to Vasospasm From a Privileged Model: the Primary Raynaud's PhenomenonCompletedNCT02202291Not applicable
• PORH and Response to Cold in Raynaud's Phenomenon.Status unknownNCT02183779Not applicable
• "As Required" Oral Sildenafil in Raynaud's PhenomenonCompletedNCT02050360Phase 2/3
• Digital Flow Enhancement in Raynaud's Phenomenon With an sGC (Soluble Guanylate Cyclase) StimulatorCompletedNCT01926847Phase 2
• Laser Speckle Contrast Imaging for Cutaneous Microvascular Dysfunction Detection in Systemic Sclerosis.CompletedNCT01743612Not applicable
• Prognostic Influence of Light Rheography Measurement of Patients With Secondary Raynaud Syndrome With Ulcers on HandsStatus unknownNCT01378845Not applicable
• Efficacy of ORM-12741 for Prevention of Raynaud's PhenomenonTerminatedNCT01315899Phase 2
• Effects of Vardenafil on Clinical Symptoms and Peripheral Blood Flow in Patients With Raynaud's SyndromeCompletedNCT01291199Phase 2/3
• A Randomized Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in SclerodermaCompletedNCT01117298Phase 3
• The Effect of Physical Therapy on Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT00946738Not applicable
• Study of a Topical Formulation for the Treatment and Prevention of Raynaud's Phenomenon SymptomsStatus unknownNCT00934427Phase 3
• MQX-503 Applied to the Hand Versus Nitroglycerin Ointment Applied to the Chest: A Pharmacokinetic ComparisonCompletedNCT00841594Phase 1
• Trial of IC351 in Female Scleroderma Patients With Raynaud's and Sexual DysfunctionCompletedNCT00707187Phase 2
• Dose Response to Topical Glyceryl Trinitrate in Patients With Raynaud's PhenomenonCompletedNCT00700518Phase 1
• Randomised Control Trial to Assess the Efficacy of Tadalafil in Raynaud's Phenomenon in SclerodermaCompletedNCT00626665Phase 3
• A Study of a Topical Form of Nitroglycerin and Placebo in the Treatment and Prevention of Raynaud's PhenomenonStatus unknownNCT00577304Phase 3
• Safety, Tolerability, and Pharmacodynamic Profile of Oral 2101 in Secondary Raynaud's DiseaseCompletedNCT00528242Phase 2
• Dose Response Study of a Topical Formulation of Nitroglycerin for the Treatment of Raynaud's PhenomenonCompletedNCT00480753Phase 2
• Phase III Study of a Topical Gel Formulation for Treatment and Prevention of Raynaud's PhenomenonCompletedNCT00419419Phase 3
• Dose Response Study of a Topical Gel for the Treatment of Raynaud's PhenomenonCompletedNCT00378521Phase 2
• St. John's Wort in the Treatment of Raynaud's PhenomenonCompletedNCT00351117Phase 3
• Phase III Study of Topical Gel for Treatment and Prevention of Raynaud's PhenomenonCompletedNCT00266669Phase 3
• Lab Study of MQX-503 in Treatment of Raynaud'sCompletedNCT00253331Phase 2/3
• Safety and Efficacy of Pletal (Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's PhenomenonCompletedNCT00048776Phase 4
• Safety and Efficacy of Pletal(Cilostazol) for the Treatment of Juvenile Primary and Secondary Raynaud's PhenomenonCompletedNCT00048763Phase 4
• Phase III Randomized, Double-Blind, Placebo-Controlled Study of Oral Iloprost for Raynaud's Phenomenon Secondary to Systemic SclerosisCompletedNCT00004786Phase 3
• Raynaud's Treatment Study (RTS)CompletedNCT00000530Phase 3

← Raynaud Disease overview